遗传病信号编排了质母细胞瘤恶性病变,并增强了temozolomide的反应
Yuanyuan Li1, Yuxin Qiu1, Wenqing Gao1
1Shanghai Pudong Hospital and School of Life Sciences, State Key Laboratory of Genetics and Development of Complex Phenotypes, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai, China.
Cell death & disease
|December 22, 2025
概括
升高的RIPK1蛋白驱动着质母细胞瘤的生长,并预测预后不佳. 激活程序性亡 (亡) 增强化疗,提供新的质瘤治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡途径 细胞死亡途径
背景情况:
- 质母细胞瘤 (GBM) 是一种具有不良预后和抗化疗能力的侵袭性脑瘤.
- 编程性亡 (necroptosis) 涉及到GBM,但其作用尚未完全理解.
研究的目的:
- 为了研究亡机械蛋白在质瘤进展中的作用.
- 评估RIPK1在GBM中的功能及其作为治疗点的潜力.
- 探索新的治疗策略,将亡诱导剂与化疗结合起来.
主要方法:
- 在质瘤患者样本中分析RIPK1和MLKL表达.
- 在实验室中使用基因剥离和RIPK1.1的药理抑制进行的研究.
- 在体内研究,使用皮下异种移植和 орто型小鼠质瘤模型.
- 评估结合性治疗效应与死亡诱导剂和temozolomide (TMZ).
主要成果:
- 较高的RIPK1和MLKL表达与GBM进展和不良预后相关.
- RIPK1促进GBM细胞的增殖,迁移和入侵,独立于其死细胞功能.
- 基因RIPK1消去抑制瘤生长,但necrostatin-1是无效的.
- 双重诱导亡和亡的药物与TMZ协同作用,改善体内质瘤细胞死亡和瘤清除.
结论:
- RIPK1是质瘤恶性病的关键驱动因素.
- 激活亡可以提高temozolomide在GBM治疗中的疗效.
- 这些发现为新的预后标志物和质瘤治疗方法提供了基础.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways
7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K


